5653-21-4 Usage
General Description
Methazonic acid is a chemical compound with the molecular formula C7H5NO3. It is a strong organic acid that is typically used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. Methazonic acid is known for its ability to form stable complexes with metal ions, making it useful in analytical chemistry for the determination of metal ions in various samples. It is also used as a reagent in organic synthesis, particularly in the preparation of heterocyclic compounds. Additionally, methazonic acid has been studied for its potential anti-inflammatory and antioxidant properties, although further research is needed to fully understand its biological activities. Overall, methazonic acid is a versatile compound with applications in various scientific and industrial fields.
Check Digit Verification of cas no
The CAS Registry Mumber 5653-21-4 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,6,5 and 3 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 5653-21:
(6*5)+(5*6)+(4*5)+(3*3)+(2*2)+(1*1)=94
94 % 10 = 4
So 5653-21-4 is a valid CAS Registry Number.
InChI:InChI=1/C2H4N2O3/c5-3-1-2-4(6)7/h1,5H,2H2/b3-1+
5653-21-4Relevant articles and documents
Drew et al.
, p. 2622,2625 (1955)
QUINOLINO-PYRROLIDIN-2-ONE DERIVATIVE AND APPLICATION THEREOF
-
Paragraph 0076; 0078, (2021/07/08)
Disclosed are a series of quinolino-pyrrolidin-2-one compounds, and application thereof in preparation of drugs for ATM inhibitor-related diseases. The present disclosure specifically relates to a derivative compound represented by formula (I), tautomers thereof or pharmaceutically acceptable compositions thereof.
IMIDAZOQUINOLINE-TYPE COMPOUNDS AND USES THEREOF
-
Paragraph 0013; 00106; 00107, (2021/10/11)
Provided in the present disclosure are imidazoquinoline-type compounds, methods for their preparation, pharmaceutical compositions thereof and their use, wherein the imidazoquinoline-type compounds, upon local administration, form depots inducing cell mediated immune response while mitigating a systemic proinflammatory immune response.